ArticleBritish journal of clinical pharmacology2019
Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016.
Article in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Centrally-acting opioid receptor antagonists as a treatment for antipsychotic-induced weight gain: A systematic review and meta-analysis of clinical trial data.Journal of psychopharmacology (Oxford, England) · 2025Pooled it
- Lurasidone versus typical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2025Pooled it
- Mental Health and Serious Drug Crime: A Case-Control Study.Criminal behaviour and mental health : CBMH · 2026Article
- From blood to brain: postmortem brain concentrations and brain-blood ratios of chlorprothixene, clozapine, olanzapine, and quetiapine.Journal of analytical toxicology · 2026Article
- Twenty-Year Trends in Antipsychotic Utilization in Serbia: A Nationwide Drug Utilization Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Trends in antipsychotic drug utilisation and indication in the paediatric population: a nationwide cohort study in Sweden.BMJ mental health · 2026Article
- Drug utilisation of antipsychotics and lithium in Sweden 2008-2021 - a nationwide study of children aged 5-17 years.European child & adolescent psychiatry · 2026Article
- Antipsychotic treatment patterns and predictors of polypharmacy in psychotic disorders: 20-year real-world data from a tertiary center.Irish journal of medical science · 2026Article
- Trends in antipsychotic and lithium use in Scandinavian countries from 2010 to 2023: a cross-country drug utilization study.BMC psychiatry · 2026Article
- Evidence of lithium underuse in bipolar disorder: analysis of lithium and antipsychotic consumption, prediction of future trends, regional disparities and indicators of rational and inappropriate use in Europe.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Antipsychotic off-label use in the 21st century: An enduring public health concern.Dialogues in clinical neuroscience · 2025Review
- Exploring Medication Errors with Antipsychotics in Saudi Arabia: Insights from a Nationwide Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Patterns and indications for quetiapine prescribing in Dutch primary care: a retrospective database study.BJGP open · 2025Article
- Real-World Evidence on Low-Dose Olanzapine (≤1.25 mg) for Personalized Antipsychotic Dosing.Journal of personalized medicine · 2025Article
- Pharmacotherapy of Psychotic Disorders in Türkiye: Insights From a National Prescription Database.Brain and behavior · 2025Article
- Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users.Acta neuropsychiatrica · 2025Article
- FDA-approved drugs containing dimethylamine pharmacophore: a review of the last 50 years.RSC advances · 2024Review
- Consumption of psychotropic drugs in Croatia before and during the COVID-19 pandemic: a 10-year longitudinal study (2012-2021).Social psychiatry and psychiatric epidemiology · 2024Article
- On- and off-label utilisation of antipsychotics in Australia (2000-2021): Retrospective analysis of two medication datasets.The Australian and New Zealand journal of psychiatry · 2024Article
- Prevalence and Cost of Antipsychotic Prescribing, within the Context of Psycholeptic Prescribing, in the Irish Setting.Healthcare (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of this study was to investigate time trends in dosing and prevalence of antipsychotic prescriptions in Scandinavia.
methodsWe retrieved data on antipsychotic use between 2006 and 2016 from Danish, Norwegian and Swedish national prescription registers. For each antipsychotic, we calculated prevalence of use and mean doses, overall and for specific age groups (young, adults and elderly).
resultsAntipsychotic use in Scandinavia increased from 16.5 to 17.2 users/1000 inhabitants between 2006 and 2016 (+2.4%, annual change: 0.07 users/1000 inhabitants/year, 95% CI: 0.02-0.20, P = 0.02). In 2006, chlorprothixene and levomepromazine were the most commonly used antipsychotics. By 2016, quetiapine was the most used antipsychotic in all three countries and across all age groups, with an overall 1-year prevalence of 4.05-9.97 users/1000 inhabitants (annual change: 0.57 users/1000 inhabitants/year, 95% CI: 0.54-0.60, P < 0.001). Quetiapine showed a marked decrease in mean doses during the 11-year study period (0.46-0.28 defined daily doses (DDD)/user/day: 39.1%, -0.02 DDD/user/day/year, 95% CI: -0.020 to -0.015, P < 0.001). In 2016, the highest mean doses were seen for clozapine (0.90-1.07 DDD/user/day) and olanzapine (0.66-0.88 DDD/user/day).
conclusionsThere is an increased prevalence of antipsychotic prescriptions that coincides with low and/or decreasing mean doses of the majority of commonly used antipsychotics in Scandinavia. Of all antipsychotics, this development was most pronounced for quetiapine. Reasons for and consequences of increased antipsychotic use that lasts shorter periods of time requires further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.